Production and in vivo use of recombinant ovine IL-1 beta as an immunological adjuvant.

[1]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[2]  F. Blecha,et al.  Immunopotentiation of bovine respiratory disease virus vaccines by interleukin-1 beta and interleukin-2. , 1993, Veterinary immunology and immunopathology.

[3]  R. Arnon,et al.  Synthetic peptides as vaccines , 1992, Current Biology.

[4]  I. Colditz,et al.  The effect of cytokines and chemotactic agonists on the migration of T lymphocytes into skin. , 1992, Immunology.

[5]  M. Brandon,et al.  Molecular cloning and characterization of ovine IL-1 alpha and IL-1 beta. , 1991, Immunology.

[6]  K. Huebner,et al.  A novel IL‐1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. , 1991, The EMBO journal.

[7]  K. Rao,et al.  Interleukin-1 derived synthetic peptide as an added co-adjuvant in vaccine formulations. , 1991, Vaccine.

[8]  C. Dinarello.  Interleukin-1 and interleukin-1 antagonism. , 1991, Blood.

[9]  S. Dower,et al.  Induction of an interleukin-1 receptor (IL-1R) on monocytic cells. Evidence that the receptor is not encoded by a T cell-type IL-1R mRNA. , 1990, The Journal of biological chemistry.

[10]  J. Playfair,et al.  Conjugation of interferon-gamma to antigen enhances its adjuvanticity. , 1990, Immunology.

[11]  S. Ohkawara,et al.  A limited role of IL-1 in immune-enhancement by adjuvants. , 1990, Immunology.

[12]  F. Blecha,et al.  Bovine recombinant interleukin-2 augments immunity and resistance to bovine herpesvirus infection. , 1989, Veterinary immunology and immunopathology.

[13]  J L Grun,et al.  Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. , 1989, Cellular immunology.

[14]  M. V. Doyle,et al.  Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Reed,et al.  IL-1 as adjuvant. Role of T cells in the augmentation of specific antibody production by recombinant human IL-1 alpha. , 1989, Journal of immunology.

[16]  G. Gallagher,et al.  The induction of protective immunity to Leishmania major in the BALB/c mouse by interleukin 4 treatment , 1989, European journal of immunology.

[17]  R. Bomford.  Adjuvants for anti-parasite vaccines. , 1989, Parasitology today.

[18]  S. Eto,et al.  Expression of IL-1 receptors on human peripheral B cells. , 1989, Journal of immunology.

[19]  A. Abbas,et al.  Role of interleukin 1 in the activation of T lymphocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Berzofsky,et al.  Recombinant human IL-2 overcomes genetic nonresponsiveness to malaria sporozoite peptides. Correlation of effect with biologic activity of IL-2. , 1988, Journal of immunology.

[21]  P. Lipsky,et al.  Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1. , 1987, Journal of immunology.

[22]  L. Nencioni,et al.  In vivo immunostimulating activity of the 163-171 peptide of human IL-1 beta. , 1987, Journal of immunology.

[23]  C. Bird,et al.  A simple sensitive bioassay for interleukin-1 which is unresponsive to 10(3) U/ml of interleukin-2. , 1987, Journal of immunological methods.

[24]  T. Hopp,et al.  The cell surface receptors for interleukin-1α and interleukin-1β are identical , 1986, Nature.

[25]  M. Robinson,et al.  Dual-origin plasmid vectors whose origin of replication is controlled by the coliphage lambda promoter pL. , 1984, Gene.

[26]  M. J. Staruch,et al.  The adjuvanticity of interleukin 1 in vivo. , 1983, Journal of immunology.

[27]  L. Chedid,et al.  Components of mycobacteria and muramyl dipeptide with adjuvant activity induce lymphocyte activating factor. , 1980, Cellular immunology.

[28]  L. Babiuk,et al.  Multiple administration with interleukin-2 potentiates antigen-specific responses to subunit vaccination with bovine herpesvirus-1 glycoprotein IV. , 1992, Vaccine.

[29]  T. Merigan,et al.  Liposome-formulated interleukin-2 as an adjuvant of recombinant HSV glycoprotein gD for the treatment of recurrent genital HSV-2 in guinea-pigs. , 1992, Vaccine.

[30]  J. Imanishi,et al.  Enhancement of the protective effect of inactivated influenza virus vaccine by cytokines. , 1992, Vaccine.

[31]  J. Playfair,et al.  Cytokines as immunological adjuvants. , 1992, Vaccine.

[32]  G. Duff,et al.  Interleukin 1: the first interleukin. , 1990, Immunology today.

[33]  A. Altman,et al.  Immunomodifiers in vaccines. , 1989, Advances in veterinary science and comparative medicine.

[34]  F. Okada,et al.  Enhancement of therapeutic effects of recombinant interleukin 2 on a transplantable rat fibrosarcoma by the use of a sustained release vehicle, pluronic gel. , 1987, Cancer research.

[35]  J. Playfair,et al.  Recombinant gamma interferon is a potent adjuvant for a malaria vaccine in mice. , 1987, Clinical and experimental immunology.

[36]  S. Dower,et al.  The interleukin-1 receptor. , 1987, Immunology today.

[37]  L. Chedid,et al.  Current status of immunological adjuvants. , 1986, Annual review of immunology.